MDX 1105

Drug Profile

MDX 1105

Alternative Names: Anti PD L1; BMS-936559; MDX-1105; PD-L1 inhibitor - Bristol-Myers Squibb

Latest Information Update: 25 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medarex
  • Class Antineoplastics; Antivirals; Monoclonal antibodies
  • Mechanism of Action CD274 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Sepsis
  • Phase I HIV infections; Solid tumours
  • Preclinical Haematological malignancies

Most Recent Events

  • 14 Sep 2017 Bristol-Myers Squibb terminates due to change in business objectives its phase I/II trial in Sepsis in USA (IV, Infusion) (NCT02576457)
  • 16 Dec 2016 Biomarkers information updated
  • 22 Feb 2016 Pharmacokinetics and adverse event results from a phase I trial in HIV Infections presented at 23rd Conference on Retroviruses and Opportunistic Infections (CROI-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top